Acino, a Swiss pharmaceutical company, has acquired South Africa’s Litha Healthcare. Litha, headquartered in Johannesburg, provides services and products to public and private hospitals, pharmacies, general and specialist practitioners, as well as government law enforcement programmes.
Acino's confidence in South Africa and Litha's strong position in the market, bode well for this collaboration that aims to maintain and further grow the pharmaceutical business in SA.
This growth happens via additional sales of existing products, new launches of in-licensed products and acquisitions of companies or product rights.
To this end, Litha will provide Acino with immediate access and a strong presence in the South African Market, which is key for Acino to become a significant player in the African pharmaceutical landscape. In turn, advanced health care products and expertise will be accessible for South Africans.
“We look forward to joining Acino as we continue to add value to our customers and positively impact patients’ lives. The synergies between the organisations will further support our vision of being one of the top 10 pharma companies in South Africa,” says Guillaume van Niekerk, Managing Director Litha Healthcare.
“We have chosen Litha as they have a strong position in the market and a solid reputation in several therapeutic areas that are strategic for Acino. With its well-established product pipeline and its long-standing relationships with licensing partners,Litha offers very promising prospects for the future,” explains Kalle Känd, CEO of Acino.
- Local scientist receives global recognition
- Life Healthcare expects revenue to surge up to 18.5%
- South Africa may ask pharma firms for fee to clear drug review backlog
- Millions of South Africans will lose access to private healthcare: FMF
- Lowest price increase in decade could see several Pharma companies exit market